Home · Health · Sep 25 archive
IBD Onset May Occur Long Before Patients Are Symptomatic
Confirmed
In Short: According to a recent study, the onset of inflammatory bowel disease (IBD) may occur long before patients become symptomatic.
Mehandru and colleagues discovered that a novel autoantibody, anti-avb6, can be detected before ulcerative colitis onset.
In patients who later developed Crohn's disease (CD), elevated herpesvirus-directed responses and anti-flagellin antibodies were found up to 10 years before diagnosis.
Their large-scale serologic profiling of archived prediagnostic samples identified disease-specific immune trajectories years before IBD onset, providing novel insights into disease pathogenesis in its prodromal phase.
Incipient immune signatures of future IBD, silently underway, may be detectable through broad serologic testing as far back as 10 years before diagnosis.
This offers new insights into the disease’s prodromal phase and a potential path toward earlier identification of high-risk patients.
The study's findings suggest that early detection could lead to earlier intervention and better management of IBD.
However, the full risks and benefits of these early detection methods may not be fully understood until more long-term studies are conducted.
What this adds
The study highlights the potential for early detection of IBD, but the long-term implications of these early immune signatures are still being explored.
What's confirmed
- Mehandru and colleagues discovered that a novel autoantibody, anti-avb6, can be detected before ulcerative colitis onset.
- In patients who later developed Crohn's disease (CD), elevated herpesvirus-directed responses and anti-flagellin antibodies were found up to 10 years before diagnosis.
- Their large-scale serologic profiling of archived prediagnostic samples identified disease-specific immune trajectories years before IBD onset, providing novel insights into disease pathogenesis in its prodromal phase.
- Incipient immune signatures of future IBD, silently underway, may be detectable through broad serologic testing as far back as 10 years before diagnosis.
- This offers new insights into the disease’s prodromal phase and a potential path toward earlier identification of high-risk patients.
- The study's findings suggest that early detection could lead to earlier intervention and better management of IBD.
- However, the full risks and benefits of these early detection methods may not be fully understood until more long-term studies are conducted.
What's still developing
- The onset of inflammatory bowel disease (IBD) may occur long before patients become symptomatic, according to a recent study.
- Republican Sen. Roger Marshall (Kansas) sued hundreds of his patients for outstanding debts and had dozens of them arrested over the course of his decades-long career as an obstetrician-gynecologist, new reporting reveals.
- Court records show that Marshall, who is running for reelection this fall, sued over 700 of his patients for debts.
- Many patients who Marshall’s office sued were new parents who had just given birth and were stuck with the delivery bill.
- And, in 81 cases, patients were arrested for missing court dates in relation to their debts — though several people interviewed by the Times said they were never notified about the court dates to begin with.
- Roger Marshall served many patients in a poor, rural part of his state.
- His practice, which he owned for over two decades, placed an 18 percent interest rate on bills for many patients — even as it served a rural area of Kansas that had a high proportion of poor and uninsured patients, for whom Marshall’s practice was the only option in the area.
- Not long ago, discovering a new drug followed a familiar, painstaking arc.
- Scientists would spend years identifying a biological target, screening thousands of compounds and refining promising leads in the lab — often with no guarantee that this effort would ultimately benefit patients.
- A major trial found that implantable cardioverter-defibrillators may benefit some patients younger than 70 with mild-to-moderate heart dysfunction and cardiac scarring.
- A more than decade-long randomized trial suggests that implantable cardioverter-defibrillators may benefit some patients who have heart scarring and only mild-to-moderate loss of heart function, a group that currently falls outside standard treatment guidelines.
- Although the devices did not significantly reduce the trial’s primary endpoint across all age groups, a prespecified analysis found a significant reduction among patients younger than 70, while sudden cardiac death was also reduced as a secondary endpoint across the full study group.